Similarly, researchers using the APPswe/PS1dE9 AD model, associated with FAD mutations in APP and γ-secretase, found that treatment with the neuroprotective compound Ligustilide reduced disease progression with a concurrent increase in PreP levels (Xu et al., 2018). This evidence concerns the gene APP and Alzheimer disease.